Briem Sveinn, Martinsson Stefan, Bueters Tjerk, Skoglund Erika
DMPK, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden.
Rapid Commun Mass Spectrom. 2007;21(13):1965-72. doi: 10.1002/rcm.3047.
In drug discovery today, drug exposure is determined in preclinical efficacy and safety studies and drug effects are related to measured concentrations rather than to the administered dose. This leads to a strong increase in the number of bioanalytical samples, demanding the development of higher throughput methods to cope with the increased workload. Here, a combined approach is described for the high-throughput preparation and liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis of drug levels in plasma samples from the preclinical efficacy and safety studies, i.e. exposure studies. Appropriate pharmacokinetic (PK) compartmental models were fitted to data from PK screening studies in the rat, which were subsequently used to simulate the expected plasma concentrations of the respective exposure studies. Information on the estimated drug concentrations was used to dilute the samples to appropriate concentration levels. A Tecan Genesis RSP liquid handling system was utilized to perform automated plasma sample preparation including serial dilution of standard solutions, dilution of plasma samples, addition of internal standard solution and precipitation with acetonitrile. This robotic sample preparation process permitted two studies of 1-96 samples each to be run simultaneously. To ensure the performance of this method the accuracy and precision for diazepam were examined. Two novel drugs were used to illustrate the suggested approach. In conclusion, our method for sample preparation of exposure samples, based on the combined use of PK simulations, a liquid handling system and a fast LC/MS/MS method, increased the throughput more than three times and minimized the errors, while maintaining the required accuracy and precision.
在当今的药物研发中,药物暴露情况是在临床前疗效和安全性研究中确定的,药物效应与测得的浓度相关,而非与给药剂量相关。这导致生物分析样本数量大幅增加,需要开发更高通量的方法来应对增加的工作量。本文描述了一种联合方法,用于临床前疗效和安全性研究(即暴露研究)中血浆样本药物水平的高通量制备及液相色谱/串联质谱(LC/MS/MS)分析。将合适的药代动力学(PK)房室模型拟合到大鼠PK筛选研究的数据,随后用于模拟各个暴露研究的预期血浆浓度。利用估计的药物浓度信息将样本稀释至合适的浓度水平。使用Tecan Genesis RSP液体处理系统进行自动化血浆样本制备,包括标准溶液的系列稀释、血浆样本的稀释、内标溶液的添加以及用乙腈沉淀。这种机器人样本制备过程允许同时进行两项各含1 - 96个样本的研究。为确保该方法的性能,检测了地西泮的准确度和精密度。使用两种新药来说明所建议的方法。总之,我们基于PK模拟、液体处理系统和快速LC/MS/MS方法联合使用的暴露样本制备方法,使通量提高了三倍多,并将误差降至最低,同时保持了所需的准确度和精密度。